Table S3.
HEC/MEC regimens
| Agent | Regimen | Schedule | Regimen type | MEC/HEC |
|---|---|---|---|---|
| Cyclophosphamide | TC | • Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 3 weeks for four cycles |
Single day | Depends on dosage |
| Cyclophosphamide/doxorubicin | TAC (with docetaxel) | • Doxorubicin 50 mg/m2 IV day 1 | Single day | HEC |
| • Cyclophosphamide 500 mg/m2 IV day 1 Cycled every 3 weeks for six cycles | ||||
| TAC (with docetaxel) | • Doxorubicin 60 mg/m2 on day 1 | Single day | HEC | |
| • Cyclophosphamide 500 mg/m2 IV day 1 Cycled every 3 weeks for four cycles | ||||
| AC | • Doxorubicin 60 mg/m2 IV day 1 | Single day | HEC | |
| • Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 2 weeks for four cycles | ||||
| • Doxorubicin 60 mg/m2 IV day 1 | Single day | HEC | ||
| • Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 3 weeks for four cycles | ||||
| • Doxorubicin 60 mg/m2 IV day 1 | Single day | HEC | ||
| • Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 3 weeks for four cycles | ||||
| • Doxorubicin 60 mg/m2 IV day 1 | Single day | HEC | ||
| • Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 3 weeks for four cycles | ||||
| FAC/CAF (with 5-FU) | • Doxorubicin 50 mg/m2 IV day 1 | Single day | HEC | |
| • Cyclophosphamide 500 mg/m2 IV day 1 Cycled every 3 weeks for six cycles | ||||
| Cyclophosphamide/epirubicin | FEC/CEF (with 5-FU) | • Epirubicin 75 mg/m2 IV day 1 | Single day | HEC |
| • Cyclophosphamide 500 mg/m2 day 1 Cycled every 3 weeks for four cycles | ||||
| EC | • Epirubicin 100 mg/m2 IV day 1 | Single day | HEC | |
| • Cyclophosphamide 830 mg/m2 IV day 1 Cycled every 3 weeks for eight cycles | ||||
| FEC | • Epirubicin 100 mg/m2 IV day 1 | Single day | HEC | |
| • Cyclophosphamide 500 mg/m2 day 1 Cycled every 3 weeks for three cycles | ||||
| FEC | • Epirubicin 90 mg/m2 IV day 1 | Single day | HEC | |
| • Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 3 weeks for four cycles | ||||
| Carboplatin | TCH | • Carboplatin AUC 6 IV day 1 Cycled every 3 weeks for six cycles |
Single day | MEC |
| CH (with trastuzumab) | • Carboplatin AUC 6 IV day 1 Cycled every 3 weeks for six cycles |
Single day | MEC | |
| CT (with docetaxel) | • Carboplatin AUC 6 IV day 1 Cycled every 3 weeks for six cycles |
Single day | MEC | |
| Cisplatin | CV (with vinorelbine) | • Cisplatin 100 mg/m2 day 1 Cycled every 4 weeks for four cycles |
Single day | HEC/depends on dosage |
| CV (with vinorelbine) | • Cisplatin 75–80 mg/m2 day 1 Cycled every 3 weeks for four cycles |
Single day | HEC/depends on dosage | |
| CG (with gemcitabine) | • Cisplatin 75 mg/m2 day 1 Cycled every 3 weeks for four to six cycles |
Single day | HEC/depends on dosage | |
| CD (with docetaxel) | • Cisplatin 75 mg/m2 day 1 Cycled every 3 weeks for four to six cycles |
Single day | HEC/depends on dosage | |
| CP (with pemetrexed) | • Cisplatin 75 mg/m2 day 1 Cycled every 3 weeks for four cycles |
Single day | HEC/depends on dosage | |
| Carboplatin | PC (with paclitaxel) | • Carboplatin AUC 6 day 1 Cycled every 3 weeks for four to six cycles |
Single day | MEC |
| PC (with paclitaxel) | • Carboplatin AUC 2 (initial) and 6 (last 2) weekly Total of three cycles |
Single day | MEC | |
| PG (with gemcitabine) | • Carboplatin AUC 2 day 1 Cycled every 3 weeks for six cycles |
Single day | MEC | |
| PE (with etoposide) | • Carboplatin AUC 2 day 1 Cycled every 4 weeks for six cycles |
Single day | MEC | |
| Oxaliplatin | FOLFOX | • Oxaliplatin 85 mg/m2 day 1 Cycled every 2 weeks for 6 months |
Single day | MEC |
| FOLFOX (modified) | • Oxaliplatin 85 mg/m2 day 1 Cycled every 2 weeks for 6 months |
Single day | MEC | |
| XELOX | • Oxaliplatin 130 mg/m2 day 1 Cycled every 3 weeks for eight cycles |
Single day | MEC |
Note: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V2.2011, Colon Cancer V3.2011, Rectal Cancer V4.2011, Small Cell Lung Cancer V2.2012, Non-Small Cell Lung Cancer V3.2011 [All accessed July 11, 2011], Antiemesis V1.2012 [Accessed August 11, 2011]. © National Comprehensive Cancer Network, Inc 2015. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
Abbreviations: MEC, moderately emetogenic chemotherapy; HEC, highly EC; TC, taxotere/cyclophosphamide; IV, intravenous; TAC, Docetaxel/doxorubicin/cyclophosphomide; AC, Doxorubicin/cyclophosphomide; FAC/CAF, Flurouracil/doxorubicin/cyclophosphomide; 5-FU, 5-fluorouracil; FEC/CEF, Cyclophosphomide/Epirubicin/Flurouracil; TCH, Docetaxel/carboplatin/trastuzumab; CH, Docetaxel/carboplatin/trastuzumab; CT, Carboplatin/trastuzumab; CV, Cisplatin/vinorelbine; CG, Cisplatin/gemicitabine; CD, Cisplatin/docetaxel; CP, Cisplatin/pemetrexed; PC, Paclitaxel/Carboplatin; PG, Paclitaxel/Carboplatin/gemicitabine; PE, Paclitaxel/Carboplatin/etoposide; FOLFOX, Folinic acid/Fluorouracil/Oxaliplatin; XELOX, Capecitabine/Oxaliplatin.